Category Archives: Urology

NICE recommends sunitinib (Sutent) for the first-line treatment of metastatic renal cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) announced in a press release that they recommend sunitinib as first line treatment for metastastatic renal cancer.

What is sunitinib? A definition from the National Cancer Institute Dictionary of Cancer Terms

A drug used to treat gastrointestinal stromal tumors (GIST) that have not responded to treatment with imatinib mesylate (Gleevec). Sunitinib maleate is also used to treat advanced kidney cancer and is being studied in the treatment of other types of cancer. It is a type of tyrosine kinase inhibitor, a type of vascular endothelial growth factor (VEGF) receptor inhibitor, and a type of angiogenesis inhibitor. Also called SU011248, SU11248, sunitinib, and Sutent.

Some further details about the decision and the role of immunotherapy in the current management of renal cell cancer:

The guidance on first line use of sunitinib has been developed on the understanding that the currently available treatment for advanced and/or metastatic renal cell carcinoma is immunotherapy (namely interferon-alfa and interleukin-2). The Institute recognises that there are people who have had or who are currently receiving immunotherapy and wish to clarify the implications of the guidance for these people. Sunitinib can be considered as a treatment option for those people with advanced and/or metastatic RCC who are currently receiving immunotherapy or who have had immunotherapy before the release of our final recommendations to ensure they are not disadvantaged by our proposed guidance.

Guidance PDF: NICE recommends sunitinib for the first-line treatment of renal cancer

Animation on the mechanism of action of GnRH agonists and antagonists in the treatment of prostate cancer

The video animations below depict the mechanism of action of GnRH agonists and antagonists in the treatment of prostate cancer. The three movies will start playing at the same time, you can right-click on each of them and deselect “play” in case you want to stop any of them. This excerpt from the Wikipedia article…

Degarelix (Firmagon) for prostate cancer: now approved by FDA

Related to EMEA’s positive opinion on degarelix (Firmagon) for prostate cancer, FDA issues this press release dated Dec. 29, 2008: FDA Approves Drug for Patients with Advanced Prostate Cancer The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer.  Continue Reading

Temsirolimus (Torisel): kinase inhibitor for the treatment of advanced renal cell carcinoma. Australian Prescriber review

From Australian Prescriber: Temsirolimus Torisel (Wyeth) vials containing 25 mg/mL concentrate Approved indication: advanced renal cell carcinoma Australian Medicines Handbook section 14.2.3 About 30% of patients with renal cell carcinoma have advanced or metastatic disease at the time of diagnosis. Chemotherapy is generally ineffective and nephrectomy is the mainstay of treatment for disease confined to…Continue Reading

Alfuzosin does not improve symptoms of chronic prostatitis- chronic pelvic pain syndrome

From JournalWatch: Alpha-Blocker Does Not Ease Symptoms of Chronic Prostatitis Alfuzosin, an alpha-adrenergic–receptor blocker, does not improve symptoms in men with chronic prostatitis–chronic pelvic pain syndrome, according to a New England Journal of Medicine study.Continue Reading

EMEA press release: CHMP positive opinion about degarelix (Firmagon) for prostate cancer

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SUMMARY OF POSITIVE OPINION for FIRMAGON International Nonproprietary Name (INN): degarelix (as acetate) On 18 December 2008 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending to grant a marketing authorisation for the medicinal product Firmagon, 80 mg and 120 mg, powder and…Continue Reading

Alpha 1 adrenergic receptors antagonists (blockers): mechanism of action animation

Additional information about alpha 1 blocking drugs.  Source: Bertram G. Katzung, Basic & Clinical Pharmacology (Mc Graw-Hill Medical, 2007) ” Phentolamine, an imidazoline derivative, is a potent competitive antagonist at both alpha 1 and alpha 2 receptors . Phentolamine causes a reduction in peripheral resistance through blockade of alpha 1 receptors and possibly alpha 2…Continue Reading

EMEA: Norfloxacin should not be used to treat acute or chronic complicated pyelonephritis

This press release was published on July 2008: EMEA recommends restricted use of oral norfloxacin-containing medicines in urinary infections The European Medicines Agency has recommended restricting the use of oral norfloxacin-containing medicines in urinary infections. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the marketing authorisations for oral norfloxacin-containing medicines,…Continue Reading

Drugs acting on the autonomic nervous system: animation showing their mechanism of action

The following is a list of drugs related to the animation: Adrenoceptor-Activating & Other Sympathomimetic Drugs Dobutamine, Ephedrine, Epinephrine, Hydroxyamphetamine, Isoproterenol, Methylphenidate, Naphazoline, Norepinephrine. Adrenoceptor Antagonist Drugs Acebutolol, Atenolol, Betaxolol, Bisoprolol, Carteolol, Carvedilo,l Carvedilol, Esmolol, Labetalol, Metoprolol, Nadolol, Pindolol, Propranolol, Sotalol, Timolol. Cholinoceptor-Activating (Acetylcholine receptor stimulants) Acetylcholine, Bethanechol, Carbachol, Cevimeline, Pilocarpine. Cholinoceptor-Blocking Drugs (Cholinoceptor antagonists)…

Toviaz (fesoterodine fumarate): new drug to treat overactive bladder

FDA press release about the approval of Toviaz (fesoterodine fumarate): The U.S. Food and Drug Administration has approved a new drug to help patients suffering from overactive bladder (OAB). Toviaz (fesoterodine fumarate) works by relaxing the smooth muscle tissue of the bladder, thus reducing the urinary frequency, urge to urinate, and sudden urinary incontinence (leakage…

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos